# Trastuzumab

## Herceptin inj 440mg

| TAH Drug Code      | [IHER](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IHER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, or initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Abdominal pain, accidental injury, asthenia, back pain, chest pain, chills, fever, flu syndrome, headache, infection, neck pain, vasodilation, GI disturbances, peripheral edema, edema, arthralgia, myalgia, anxiety, depression, dizziness, insomnia, paresthesia, somnolence, asthma, cough increased, dyspnea, epistaxis, lung disorders, pleural effusion, pharyngitis, rhinitis, sinusitis, pruritus, rash. Cardiovascular: Edema (8% monotherapy ), Peripheral edema (5% to 10% ), Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% ), Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy ), Loss of appetite (14% monotherapy ), Nausea (6% to 33% ), Vomiting (3.5% to 23% ) Hematologic: Anemia (4% ), Febrile neutropenia (23% adjuvant therapy ), Leukopenia (3% ), Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% ), Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% ), Dizziness (4% to 13% ), Headache (6% to 26% ), Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% ), Dyspnea (3% to 22% ), Pharyngitis (12% monotherapy ), Rhinitis (2% to 14% ) Other: Fever (6% to 36% ) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

## HERCEPTIN inj 600mg/5mL

##### 臨採

| TAH Drug Code      | [IHER6](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IHER6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, adjuvant treatment, breast cancer, metastatic, gastric cancer, metastatic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | 600 mg (600 mg trastuzumab and 10,000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell proteins, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | >10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%), chills (5% to 32%), headache (10% to 26%), insomnia (14%), dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%), diarrhea (7% to 25%), vomiting (4% to 23%), abdominal pain (2% to 22%), anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%), back pain (5% to 22%) Respiratory: Cough (5% to 26%), dyspnea (3% to 22%), rhinitis (2% to 14%), pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%, chills and fever most common; severe: 1%), fever (6% to 36%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Ogivri inj 440 mg (健保)

##### 臨採

| TAH Drug Code      | [IOGI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOGI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, or initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common Dermatologic: Rash (Adjuvant breast cancer, 4%; metastatic breast cancer, 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% ), Nausea (Adjuvant breast cancer, 6%; metastatic breast cancer, 33% to 76% ), Stomatitis (24% ), Vomiting (Adjuvant breast cancer, 3.5%; metastatic breast cancer, 23% to 53% ) Hematologic: Anemia, All Grades (4% to 36% ), Neutropenia, All Grades (Breast cancer, 6.4%; gastric cancer, 78% ), Thrombocytopenia, All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer, 6.2% to 10%; metastatic breast cancer, 26% to 44% ), Insomnia (Adjuvant breast cancer, 4.3%; metastatic breast cancer, 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer, 5%; metastatic breast cancer, 26% to 43% ) Other: Fatigue (29.5% to 35% ), Fever (Adjuvant breast cancer, 6%; metastatic breast cancer, 36% to 56%; gastric cancer, 18% ), Shivering (Adjuvant breast cancer, 5%; metastatic breast cancer, 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% ), Heart failure (Adjuvant breast cancer, 0.4% to 3.2%; metastatic breast cancer, 7% to 28% ), Left ventricular cardiac dysfunction (5% to 18.5% ), Myocardial ischemia, Grade 3 or 4 Hematologic: Febrile neutropenia (23% ), Neutropenia, Grade 3 or 4 (32% to 34% ), Thrombocytopenia, Grade 3 or 4 (5% ), Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer, 2.4% to 11.8%; metastatic breast cancer, 22% to 42% ), Interstitial pneumonia, acute (0.2% to 0.7% ), Pulmonary hypertension (0.2% ), Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% ), Tumor lysis syndrome |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Ogivri inj 440 mg (絕對自費)

##### 臨採

| TAH Drug Code      | [IOGIS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOGIS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, or initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common Dermatologic: Rash (Adjuvant breast cancer, 4%; metastatic breast cancer, 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% ), Nausea (Adjuvant breast cancer, 6%; metastatic breast cancer, 33% to 76% ), Stomatitis (24% ), Vomiting (Adjuvant breast cancer, 3.5%; metastatic breast cancer, 23% to 53% ) Hematologic: Anemia, All Grades (4% to 36% ), Neutropenia, All Grades (Breast cancer, 6.4%; gastric cancer, 78% ), Thrombocytopenia, All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer, 6.2% to 10%; metastatic breast cancer, 26% to 44% ), Insomnia (Adjuvant breast cancer, 4.3%; metastatic breast cancer, 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer, 5%; metastatic breast cancer, 26% to 43% ) Other: Fatigue (29.5% to 35% ), Fever (Adjuvant breast cancer, 6%; metastatic breast cancer, 36% to 56%; gastric cancer, 18% ), Shivering (Adjuvant breast cancer, 5%; metastatic breast cancer, 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% ), Heart failure (Adjuvant breast cancer, 0.4% to 3.2%; metastatic breast cancer, 7% to 28% ), Left ventricular cardiac dysfunction (5% to 18.5% ), Myocardial ischemia, Grade 3 or 4 Hematologic: Febrile neutropenia (23% ), Neutropenia, Grade 3 or 4 (32% to 34% ), Thrombocytopenia, Grade 3 or 4 (5% ), Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer, 2.4% to 11.8%; metastatic breast cancer, 22% to 42% ), Interstitial pneumonia, acute (0.2% to 0.7% ), Pulmonary hypertension (0.2% ), Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% ), Tumor lysis syndrome |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

